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http://dx.doi.org/10.1016/j.stemcr.2016.09.011SUMMARYWe established two human embryonic stem cell (hESC) lines with a GGGGCC expansion in the C9orf72 gene (C9), and compared them
with haploidentical and unrelated C9 induced pluripotent stem cells (iPSCs). We found a marked difference in C9 methylation between
the cells. hESCs and parental fibroblasts are entirely unmethylated while the iPSCs are hypermethylated. In addition, we show that the
expansion alters promoter usage and interferes with the proper splicing of intron 1, eventually leading to the accumulation of repeat-
containing mRNA following neural differentiation. These changes are attenuated in C9 iPSCs, presumably owing to hypermethylation.
Altogether, this study highlights the importance of neural differentiation in the pathogenesis of disease and points to the potential role of
hypermethylation as a neuroprotective mechanism against pathogenic mRNAs, envisaging a milder phenotype in C9 iPSCs.INTRODUCTION
Amyotrophic lateral sclerosis (ALS, OMIM #105400) is
characterized by progressive muscle weakness and atrophy
due to the degeneration of upper and lower motor neu-
rons in the brain and spinal cord, while frontotemporal
degeneration (FTD, OMIM #600274) affects behavior and
cognition, and is caused by the preferential loss of neurons
in the frontal and temporal lobe cortices. Most people who
develop ALS/ALS-FTD are between the ages of 40 and 70
years, and die within 2–5 years from diagnosis. Currently
there is no cure for ALS-FTD.
The leading known cause of ALS-FTD is a GGGGCC
repeat expansion in the first intron of the C9orf72
gene (termed C9 mutation), between noncoding exons
1a and 1b (DeJesus-Hernandez et al., 2011; Dols-Icardo
et al., 2014). This mutation can manifest as ALS, FTD, or
a combined phenotype, and accounts for 20%–80% of
familial and 5%–15% of sporadic ALS and FTD cases
(reviewed by Cruts et al., 2013). While in most people
the number of GGGGCC repeats is steady and varies be-
tween 2 and 19 units, in ALS-FTD it abnormally expands
to more than 30 copies and becomes increasingly unsta-
ble (Dols-Icardo et al., 2014). The mechanism by which
the C9 mutation leads to selective death of neurons is
unknown, and thenormal functionofC9orf72 is just begin-
ning to be defined. Multiple mechanisms for C9/ALS-FTD
have been suggested, including haploinsufficiency, RNAStem Cell R
This is an open access article under the Ctoxicity, and abnormal translation of expanded repeat se-
quences by RAN translation (reviewed by Gendron et al.,
2014). However, whether the C9 related neurodegenera-
tion is initiated via a gain-of-function (toxic RNA and/or
unconventional dipeptide translation) or a loss-of-func-
tion mechanism is still under investigation in animal and
cellular models.
The GGGGCC repeat sequence is flanked by two CpG
islands (CGIs) within a 1-kb region that spans from
the promoter sequence into intron 1 of C9orf72. Like
many CGIs in the genome, this region typically remains
free of DNA methylation in subjects with 2–90 repeats.
Yet large expansions lead to the formation of one large
CGI with abnormal CpG methylation at the repeats (Xi
et al., 2015b), which could spread to the 50 upstream
CGI in up to 37% of C9 cases (Belzil et al., 2014; Gijse-
linck et al., 2015; Liu et al., 2014; Russ et al., 2015; Xi
et al., 2013, 2014, 2015a, 2015b). Hypermethylation is
suggested to be coupled with the local gain of repressive
histone modifications (H3K9me3 and H3K27me3) (Belzil
et al., 2013; Zeier et al., 2015). It is still unclear how,
or whether, hypermethylation contributes to disease
pathogenesis. While some reports demonstrate an overall
decrease in C9orf72 transcription, others show a change
in the relative distribution between the three different
mRNA isoforms, favoring transcription from exon
1a (V1 and V3, NM_145005.5 and NM_001256054.1,
respectively) over exon 1b (V2, NM_018325.3) (Donnellyeports j Vol. 7 j 927–940 j November 8, 2016 j ª 2016 The Authors. 927
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et al., 2013; Haeusler et al., 2014; Lee et al., 2013). While
previous reports failed to detect a correlation between
hypermethylation and ALS versus FTD phenotype (Xi
et al., 2015b), experimental evidence demonstrates that
C9orf72 haploinsufficiency affects cell morphology and
function of motor neurons in zebrafish (Ciura et al.,
2013). On the other hand, hypermethylation protects
against the accumulation of pathogenic RNA foci and
dipeptides, caused by the repeat-containing mRNA vari-
ants 1 and 3 (Bauer, 2016; Day and Roberson, 2015; Liu
et al., 2014). These conflicting results warrant further
investigation regarding the contribution and timing of
C9orf72 hypermethylation in ALS-FTD pathogenesis,
and the discrepancies may be resolved by the use of
in vitro derived neurons from C9/ALS-FTD pluripotent
cells. Indeed, induced pluripotent stem cells (iPSCs)
from C9/ALS patient fibroblasts have already been used
to generate motor neurons in culture that recapitulate
the key neuropathological features of FTD-ALS (Almeida
et al., 2013; Cooper-Knock et al., 2014, 2015; Devlin
et al., 2015; Donnelly et al., 2013; Li et al., 2015;
Peters et al., 2015; Rossi et al., 2015; Sareen et al., 2013;
Satoh et al., 2014; Wainger et al., 2014). Nevertheless,
the epigenetic aspects of the disease have never been
addressed using this model system. The aim of this study
is to characterize the methylation state of the expanded
region and explore its effect on C9orf72 variant transcrip-
tion in C9/ALS human embryonic stem cells (hESCs),
and compare them with that of their haploidentical
(mother-to-child genetic identity) and unrelated C9
iPSCs before and after differentiation.RESULTS
Derivation and Characterization of C9/hESC Lines
We established two hESC lines with a C9 mutation (SZ-
ALS1 and SZ-ALS3) from embryos, which were obtained
through preimplantation genetic diagnosis (PGD) and
donated for cell line derivation by a family in which the
mother was an expansion carrier (patient H, 30 years old,
originally diagnosed as a carrier of an expansion with >40
repeats in blood by a repeat primed PCR (rp-PCR); data
not shown). Our newly established C9 hESC lines display
the key features of pluripotent cells, namely unrestricted
growth in culture, expression of undifferentiated cell-
specific markers, and potential to differentiate into a
wide range of cell types by forming teratomas (Figure S1A,
B, D). Chromosome analysis by Giemsa staining demon-
strated a 46(XX) karyotype for SZ-ALS1 and a 45(X0) for
SZ-ALS3 (Figure S1C). Southern blot analysis identified a
GGGGCC expansion of at least 270 repeats in both cell
lines (Figure S1E).928 Stem Cell Reports j Vol. 7 j 927–940 j November 8, 2016Analysis of C9orf72Methylation in C9 hESCs and
Their Haploidentical iPSCs
Considering the accumulated data regarding hyperme-
thylation in C9 carriers, we aimed to determine whether
hypermethylation is already established in the undifferen-
tiated state. Therefore we examined methylation levels,
200 bp upstream of the 50 end of the GGGGCC repeats,
by bisulfite DNA colony sequencing in the C9 hESCs
(24 CpG sites). Interestingly, despite the presence of a large
expansion, methylation was almost 0% in both cell lines
(Figure 1A). To exclude the possibility that methylation
had already begun, but failed to spread further upstream
to the 50 CGI, we searched for methylation at the 50 end
of the repeats by carrying out a qualitative (G4C2)n-methyl-
ation assay that is sensitive enough to detect repeat
methylation in themixture containing only 2%–5%highly
methylated DNA (Xi et al., 2015b). Here again, methyl-
ation was undetectable in the mutant hESCs (Figure 1B).
In contrast, the expanded allele in whole blood cells of
the mother revealed methylation, although weak, in the
expansion itself and the 50 flanking region (estimated as
5% by bisulfite sequencing) (Figures 1A and 1B).
To generate a complement model system, we established
haploidentical (genetically half-identical) iPSCs (more
than ten different clones) from skin fibroblasts of the
currently asymptomatic mother with a C9 expansion,
who donated the embryos for hESC line derivation. The
primary fibroblasts, which had an unmethylated 700-
repeat expansion (Figure S2D), were reprogrammed by
standard protocol using Yamanaka’s four transcription
factors (Takahashi et al., 2007). The newly established
C9 iPSCs with typical ESC morphology demonstrated
unrestricted self-renewal, expressed undifferentiated cell-
specific markers, and presented a normal karyotype (Fig-
ure S2A–C). By comparing their methylation status with
that of the C9 hESCs and parental fibroblasts, we found
that the C9 iPSC clones were unusual in their methylation
levels. Unlike hESCs and primary fibroblasts, methylation
was exceptionally high in the iPSCs. Bisulfite DNA colony
sequencing of the region upstream of the expansion iden-
tified 50% fully methylated DNA copies in all iPSC clones,
suggesting complete methylation of the mutant allele (Fig-
ure 1C). The (G4C2)n-methylation assay revealed hyperme-
thylation of the repeats at the 50 end of the expansion
exclusively in C9 iPSCs (Figure 1D). However, while the up-
stream flanking region of the mutant allele was completely
methylated based on bisulfite DNA sequencing (50%), the
GGGGCC repeats themselves were not methylated in all
DNA molecules (evidenced by signals of repeats beyond
the normal range in both the green and blue channels in
the (G4C2)n-methylation assay). Importantly, differential
methylation between the iPSCs and their parental fibro-
blasts could not be attributed to the increase in repeat
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number, since expansion size remained steady following
cell reprogramming, as determined by Southern blot anal-
ysis (Figure S2D). In addition, as expansion size in the C9
hESCs is well above the threshold necessary to elicit hy-
permethylation in C9orf72 in any other cell type thus far
examined, it is very unlikely that the striking differences
in hypermethylation between the C9 iPSCs and their C9
hESCs counterparts stem from a difference in expansion
size. We further confirmed the fundamental difference in
the epigenetic state of the C9 mutation between both
cell types by demonstrating significant enrichments for
the repressive histone modification H3K9me3 by chro-
matin immunoprecipitation (ChIP) analysis exclusively in
mutant iPSCs (Figure 2A). No enrichments for H3K27me3
could be detected in wild-type (WT) or affected hESCs and
iPSCs (Figure 2B). Taken together, these findings suggest
that reprogrammingalters the epigenetic stateof this region
as a consequenceof the expansion in iPSCs, likely spreading
from the 50 border of the CGI toward the repeats.
Methylation Analysis in C9 iPSCs Derived from an
Unrelated Symptomatic ALS Patient
To further corroborate our findings and examine whether
methylation is affected by age or disease symptoms, we
also generated iPSCs from a skin biopsy of a 65-year-old
C9 ALS patient, 2 years following disease onset (patient
M). Southern blot analysis demonstrated the presence of
a 2,700 repeat expansion in the primary fibroblasts of
the patient (Figure S2D). Reprogramming of these fibro-
blasts led to the establishment of more than ten different
C9 iPSC clones. The newly established C9 ALS patient-
derived iPSCs had the typical characteristics of hESCs (Fig-
ure S2). By comparing expansion size and methylation
levels between the iPSCs and their parental fibroblasts we
found that, although expansion size remained the same,
methylation levels at the 50 CGI dramatically increased
from 0% in parental fibroblasts to 50% in affected iPSCs,
suggesting methylation levels of 100% on the expanded
allele as determined by bisulfite colony sequencing (Fig-
ure 3A). The (G4C2)n-methylation assay indicated methyl-
ation of the repeats at the 50 end of the expansion, butFigure 1. Analysis of Methylation Levels in the Upstream Region
Maternal Blood, Primary Fibroblasts, and iPSCs Derived from Them
(A) Methylation levels upstream of the repeats were determined by
(altogether 24 CpG sites) in SZ-ALS1, SZ-ALS3, and wild-type (WT) (SZ
represents a single DNA molecule (upstream region of the repeats), wit
circles, respectively.
(B) Results of the (G4C2)n-methylation assay in WT and affected (C9/AL
represents methylated alleles, while the right panel (green channel)
(C) Methylation levels upstream to the repeats as determined by singl
WT iPSCs, C9 parental fibroblasts (from patient H) and iPSCs derived
(D) Results of the (G4C2)n-methylation assay in WT and C9 affected c
930 Stem Cell Reports j Vol. 7 j 927–940 j November 8, 2016not in the parental fibroblasts (Figure 3B). These results pro-
vide further evidence that somatic cell reprogramming
excessively hypermethylates the 50 UTR of the C9orf72 lo-
cus. In addition, we examined the methylation status of a
different gene, SIGLEC6, as a reference locus for aberrant
de novo methylation by transcription factor reprogram-
ming, independent of the method used (integratable and
nonintegratable vectors) (Huang et al., 2014). Here again,
methylation was exclusively acquired in all iPSCs (WT
and C9-iPSCs), but was completely absent in primary fibro-
blasts (patients H and M) or hESCs (SZ-ALS1 and SZ-ALS3)
(Figure S3). However, unlike in C9orf72, hypermethylation
in SIGLEC6 is not conditioned by a change in the DNA
sequence.
The Effect of Differentiation on the Methylation
Status of C9orf72
To explore the effect of differentiation on the methylation
status of the C9 mutation, we induced the unmethylated
mutant hESCs (SZ-ALS1 and SZ-ALS3) and C9 hypermethy-
lated iPSC clones (H#8 and M#9) to differentiate into dis-
ease-relevant cell types, i.e., neural precursor cells (NPCs)
and neural-enriched teratomas. For NPCs, we applied a
commonly used and highly efficient differentiation proto-
col that relies on the generation of neural rosettes by the
use of two inhibitors (dorsomorphin and SB431542) (Fig-
ure S4A) (Kim et al., 2010). Differentiation efficiency into
NPCs was assessed by fluorescence-activated cell sorting
(FACS) analysis for NCAM1-positive cells (above 90%, Fig-
ure S4B), and by monitoring for the expression of early
neural differentiation markers SOX2, Nestin, and PAX6 by
RT-PCR (Figure S4C). In addition we took advantage of
the teratomas, which are highly enriched for mature neu-
rons (assessed by histological examination [H&E staining,
Figures S1] and the presence of Tuj1-expressing cells [Fig-
ure S4D]), to explore the effect of differentiation on
the methylation levels of the mutation. Interestingly,
methylation levels remained unchanged as determined
by bisulfite colony sequencing. In the NPCs and teratomas
generated from C9 hESCs, methylation remained at 0%,
while in the NPCs and teratomas produced from C9 iPSCsof the G4C2 Repeats and in the G4C2 Repeat Itself in C9 hESCs,
bisulfite sequencing of a region 200 bp upstream of the repeats
-13) hESCs and whole blood from the mother (patient H). Each line
h methylated and unmethylated CpGs designated by black and white
S) hESCs and blood cells of the mother. The left panel (blue channel)
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Figure 2. ChIP Analysis for H3K9me3 and H3K27me3 in WT and
C9 Fibroblasts, Undifferentiated hESCs, and iPSCs
Real-time PCR ChIP analysis for (A) H3K9me3 and (B) H3K27me3 in
WT and C9 affected hESCs (SZ-ALS1 and SZ-ALS3), haploidentical
parental fibroblasts (Fib-H), and iPSCs derived from them (C9-iPS
#H8 and #H10). APRT was used as a negative control for both
modifications. Negative controls were set to 1. The data in each
panel represent an average of three to five independent ChIP
experiments. Error bars represent SE (paired t test, **p < 0.01,
***p < 0.001).methylation remained at 50% (Figures 4A and 4C). These
results were further validated by the (G4C2)n-methylation
assay (Figures 4B and 4D).
The Effect of Hypermethylation on C9orf72
Expression
To explore whether the expansion alters C9orf72 gene
expression and to examine whether it corresponds with
hypermethylation, we determined the mRNA levels of
the three isoforms (see schematic illustration in Figure 5A)
in WT as well as C9 hESCs and iPSCs. Targeting transcript
variants 1 (V1), 2 (V2), and 3 (V3) individually (amplicons
spanning exon boundaries 1a-2 and 1b-2), and all together
(amplicon spanning exon boundaries 2–3) with TaqMan
probes, we show that while the general levels of C9orf72
(V1 + V2 + V3) as well as of V2 and V3 remain unchangedbetween WT and C9 cells in hESCs and iPSCs (Figure 5B),
V1 alone is significantly higher in mutant versus WT un-
differentiated cells (t test for equal variances, p < 0.05) (Fig-
ure 5B). Nevertheless, upregulation of V1 is at least 2.5-fold
higher in C9 hESCs relative to C9 iPSCs (t test for equal
variances, p < 0.05) (Figure 5B). Given the high abundance
of V2 relative to the other variants (cycle threshold [Ct]
values of 26–27 versus 27–34), the change in V1, even
though significant, reflects minute differences overlooked
when measuring overall levels of C9orf72 mRNA. We
conclude that the GGGGCC expansion alters the region
leading to the increased expression of C9orf72 V1 tran-
scripts in C9 iPSCs.
To explore whether neural differentiation contributes
to the change in C9orf72 transcription, we also assayed
the various isoforms upon differentiation into NPCs and
teratomas. Interestingly, we found that differentiation of
C9 hESCs into both cell types further enhanced the tran-
scription of exon 1a-bearing transcripts by increasing the
expression of both V3 and V1 (Figure 5C). This is in
contrast to the upregulation of V2 (the most abundant
transcript) in NPCs and teratomas of C9 iPSCs, contrib-
uting to the overall increase in C9orf72 mRNA levels (Fig-
ure 5C). Jointly, these findings demonstrate that the C9
mutation, together with neural differentiation, favors tran-
scription from the upstream promoter. This effect is largely
restricted in iPSCs, presumably due to hypermethylation.
Considering the central role of intron 1-retaining tran-
scripts in the pathology of C9/ALS-FTD disease (Niblock
et al., 2016), we aimed to search for the expression of
repeat-containing mRNAs in C9 cells. First we generated
rRNA-depleted RNA sequencing (RNA-seq) libraries from
WT as well as C9-mutant undifferentiated hESCs (two cell
lines) and iPSCs (five clones), and RNA deep-sequenced
them utilizing next-generation sequencing (see Figures
S5A and S5B for general coverage and amount of reads in
intron 1 relative to exon 2 of C9orf72 and the RNA-seq
data at GEO: GSE87273). As anticipated and in agreement
with the report of Niblock et al. (2016), by zooming in to
the 50 part of C9orf72 we found preferential retention of
intron 1 in bothC9hESCs and iPSCs (Figure 6A), indicating
the propensity of the mutation to interfere with proper
splicing of this region. However, quantifying this change
between mutant and unaffected cells demonstrates a
greater effect in hESCs (4.5-fold increase) relative to iPSCs
(only 2-fold increase) (Figure 6B). Considering that C9 cells
carry both the allele with expansion and a normal allele,
these fold changes are predicted to reflect even greater dif-
ferences in expression betweenWTand mutant alleles. We
conclude that the shift in promoter usage is coupled with
the general tendency to retain intron 1 by the expansion.
Next, we aimed to explore whether this may promote accu-
mulation of repeat-containing mRNA transcripts (exonStem Cell Reports j Vol. 7 j 927–940 j November 8, 2016 931
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Figure 3. Analysis of Methylation Levels in the Region Upstream of the G4C2 Repeats and in the G4C2 Repeat Itself in Primary
Fibroblasts and iPSCs Derived from Patient M
(A) Methylation levels upstream of the repeats were determined by bisulfite sequencing of the same region as in Figure 1A in WT and C9
affected parental fibroblasts derived from a 65-year-old C9/ALS-manifesting patient (patient M) and iPSCs derived from them (C9 iPS#M1,
iPS#M9, and iPS#H10). Each line represents the upstream region of the repeats, with methylated and unmethylated CpGs designated by
black and white circles, respectively.
(B) Results of the (G4C2)n-methylation assay in primary fibroblasts and iPSC clones derived from patient M. Left panel (blue channel)
represents methylated alleles while the right panel (green channel) represents unmethylated alleles.1a-initiating transcripts that retain repeat expansion),
which form the underlying mechanism for protein/RNA
gain of function in C9/ALS-FTD. cDNA sequencing at
the boundary between intron 1 and exon 5 confirmed
the existence of such transcripts in our cells (Figure S5).
Using primers located upstream of the repeats that specif-
ically target repeat-containing mRNAs in undifferentiated
(hESCs and iPSCs, Figure 6C) and differentiated (NPCs
and teratomas, Figure 6D) cells, we monitored for the
existence of these unusual mRNAs by real-time RT-PCR.
Importantly, while no difference could be detected be-
tween C9 andWTundifferentiated cells (hESCs and iPSCs),
their level became significantly higher upon differentia-
tion into NPCs and teratomas exclusively in C9 hESCs
(7.8- and 2.6-fold change, respectively) (Figures 6D and S5),
and not in C9 iPSCs. Hence, our findings provide evidence932 Stem Cell Reports j Vol. 7 j 927–940 j November 8, 2016that the C9 mutation interferes with proper splicing of
intron 1, thereby enhancing the formation of potentially
pathogenic repeat-containing mRNAs upon differentia-
tion. Importantly, this effect is missing in C9 iPSCs, pre-
sumably due to hypermethylation.DISCUSSION
We report on the derivation and full characterization of
two hESC lines (SZ-ALS1 and SZ-ALS3) with a GGGGCC
expansion of approximately 270 repeats. Our C9 hESC
lines were established from embryos obtained through
PGD from a woman with a C9 mutation with >40 repeats
in her peripheral blood. Interestingly, despite the suffi-
ciently large expansion, both cell lines were completely
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Neural Precursors and Teratomas Derived
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(A) Methylation levels upstream to the repeats
were determined by bisulfite sequencing in
teratomas and neural precursor cells (NPC)
derived fromWT and C9mutant hESCs (SZ-ALS1
and SZ-ALS3). Each line represents a single
DNA molecule (upstream region of the re-
peats), with methylated and unmethylated
CpGs designated by black and white circles,
respectively.
(B) Results of the (G4C2)n-methylation assay
in WT and affected (C9) teratomas and NPCs
derived from hESCs. Left panel (blue channel)
represents methylated alleles while the
right panel (green channel) represents un-
methylated alleles.
(C) Methylation levels upstream of the repeats
were determined by bisulfite sequencing in
teratomas and NPCs derived from WT and C9
iPSCs from patient H (C9-iPSC H#8, 700 re-
peats) and patient M (C9-iPSC M#9, 2,700 re-
peats). Each line represents a single DNA
molecule (upstream region of the repeats),
with methylated and unmethylated CpGs
designated by black and white circles,
respectively.
(D) Results of the (G4C2)n-methylation assay
in WT and affected (C9/ALS) teratomas and
NPCs derived from iPSCs. Left panel (blue
channel) represents methylated alleles while
right panel (green channel) represents un-
methylated alleles.
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unmethylated at the repeats (based on (G4C2)n-methyl-
ation assay [Xi et al., 2015a, 2015b]) and upstream of the
repeats (based on bisulfite colony sequencing). In addition,
we generated iPSCs clones that are haploidentical to the
mutant hESCs from skin fibroblasts of the asymptomatic
C9-carriermother (700 repeats, patient H), and from an un-
related 65-year-old ALS-manifesting patient (2,700 repeats,
patient M). Unexpectedly, we found a striking difference
in methylation levels at the 50 UTR of C9orf72 between
the C9 iPSCs and all other cell types examined. Unlike in
the C9 hESCs and parental fibroblasts, methylationwas de-
tected at the expanded repeats, and reached almost 100%
at the upstreamCGI in all iPSC clones. Although the differ-
ence in C9orf72 hypermethylation between the C9 hESCs
and iPSCs could, in theory, result from a difference in
expansion size, this is very unlikely since the number of
GGGGCC repeats in the hESCs is well above the threshold
for methylation to be triggered in any cell type examined
thus far (Xi et al., 2015b). In addition, methylation levels
in the iPSCs are much higher than those observed in so-
matic cells of patients (where it does not exceed 20% [Liu
et al., 2014]), and is consistent with the exclusive enrich-
ment of the repressive histone mark H3K9me3 and not
H3K27me3. This is somewhat different from the data ob-
tained by Belzil et al. (2013), who demonstrated enrich-
ments for H3K27me3 in addition to H3K9me3, although
they analyzed different cell types from those described
in this study. While we used undifferentiated cells, they
looked at frontal cortex and cerebellum. Indeed, our find-
ings in undifferentiated cells cast doubt on the importance
of H3K27me3 modification for setting the methylation
state and transcriptionally inactive chromatin configura-
tion at the C9 expansion.
We argue that the C9 mutation acts as a hotspot for de
novo methylation by transcription factor reprogramming
considering the dramatic rise in DNA methyltransferase
3B (DNMT3B) expression levels during the reprogramming
procedure (Huang et al., 2014). In fragile X syndrome it was
also shown that reprogramming of fibroblasts with an
unmethylated full CGG expansion results in hypermethy-
lation and complete inactivation of the FMR1 gene inFigure 5. Analysis of C9orf72 Variant Expression Levels in Undiff
qRT-PCR
(A) Schematic illustration of the three C9orf72 mRNA isoform variant
(B and C) Mean value of qRT-PCR for C9orf72 transcription in both C
patients H (H8, H10) and M (M1, M9, M10), and their WT controls from
2, and 3. mRNA transcription levels were determined in (B) undifferent
and teratomas) of C9 mutation carrying cells and appropriate controls
variants 1, 2, and 3 individually (V1, V2, V3) as well as altogether (V1
variant. The expression level in each cell type represents an average o
were normalized to the corresponding Ct value of GUS. WT hESC line is
**p < 0.01, ***p < 0.001).mutant iPSCs (de Esch et al., 2014). Thus, perhaps hyper-
methylation of the GGGGCC repeats in our C9 iPSCs rep-
resents a much wider phenomenon, whereby untranslated
repeat expansions that reside within CGIs provide a ‘‘sink’’
for DNMTs during transcription factor reprogramming
(rather than first de novo methylate and then failure to
demethylate). This may also explain why we and others
generally fail to demethylate and reactivate the FMR1
gene by somatic cell reprogramming when producing
iPSCs from cells of fragile X-affected patients (Avitzour
et al., 2014; Sheridan et al., 2011; Urbach et al., 2010). It
should be noted that our results contradict the report of
Esanov et al. (2016), who showed demethylation (rather
than de novomethylation) of theC9mutation inC9 iPSCs.
The discrepancy could result from the different cell states
employed.We used primary skin fibroblasts from two unre-
lated patients, whereas they used an immortalized cell line
from blood cells of a single patient.
Toexplore theeffect ofdifferentiationonthemethylation
status of the C9 mutation, we induced the unmethylated
mutant hESCs (SZ-ALS1 and SZ-ALS3) and C9 hypermethy-
lated iPSC clones (fromC9 individualsH andM) to differen-
tiate into disease-relevant cell types (NPCs and teratomas),
which are generally enriched in neural cells. Interestingly,
methylation levels remained unchanged at the repeats
and upstream of them in both hESCs and iPSCs, following
in vitro and in vivo differentiation (0% and 50%, respec-
tively). Perhaps extending differentiation length to fully
matured neurons, or to specific subtypes of neurons, would
have elicited C9 methylation in the hESCs.
Finally, to associate hypermethylation with disease path-
ogenesis, we analyzed the expression of transcript variants
1, 2, and 3 individually.We show that theGGGGCCexpan-
sion alters the region to allow the enhancement of V1 tran-
scripts, albeit with much lower levels in iPSCs relative to
hESCs. In addition, we demonstrate that the C9 mutation,
together with neural differentiation, favors transcription
from an upstream promoter (exon 1a-initiating transcripts,
V1 and V3) over a downstream promoter (exon 1b-initi-
ating transcript, V2), and that this effect is largely restricted
in iPSCs. Furthermore, we found preferential retention oferentiated and Differentiated Derivatives of hESCs and iPSCs by
s (V1, V2, and V3).
9 hESC lines (SZ-ALS1 and SZ-ALS3), C9 iPSC clones derived from
the TaqMan gene expression assay for C9orf72 transcript variants 1,
iated (hESCs and iPSCs) and (C) differentiated cell derivatives (NPCs
(WT hESCs and WT iPSCs). Using TaqMan probes targeting transcript
+ V2 + V3), we determined the relative abundance of each transcript
f three to six independent experiments. Cycle threshold (Ct) values
SZ-13. Error bars represent SE (t test for equal variances, *p < 0.05,
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Figure 6. Expression of Intron 1-Retaining C9orf72 Transcripts in Undifferentiated and Differentiated hESCs and iPSCs
(A) Genebrowser view of the first three exons (exons 1a, 1b, 2, and 3) and intronic sequences of C9orf72.
(B) Quantification of the intron 1 retention data presented in (A) in undifferentiated WT and C9 hESCs and iPSCs is based on RNA-seq data.
C9 iPSC clones from patient H and M were averaged.
(C) Relative expression levels of intron 1-retaining exon 1a-initiating transcripts as determined by real-time RT-PCR in undifferentiated C9
hESCs (SZ-ALS1 and SZ-ALS3), C9 iPSC clones, and their appropriate WT controls.
(D) Relative expression levels of intron 1-retaining exon 1a-initiating transcripts as determined by real-time RT-PCR in teratomas and NPCs
derived from C9 hESCs (SZ-ALS1 and SZ-ALS3), C9 iPSC clones, and their appropriate WT controls. The expression level in each cell type
represents an average of three to six independent experiments.
In (C) and (D), Ct values were normalized to the corresponding Ct value of GUS. WT hESC line is SZ-13. Error bars represent SE (t test for
equal variance, **p < 0.01, ***p < 0.001).intron 1 in both C9 hESCs and iPSCs by RNA deep
sequencing, illustrating the propensity of the mutation to
interfere with the proper splicing of this region in both
exon 1a- and 1b-initiating transcripts. However, this
change between WT and C9 cells demonstrates a greater
effect in hESCs (4.5-fold increase) relative to iPSCs (only a
2-fold increase). More importantly, by monitoring for
the expression of potentially pathogenic mRNA transcripts
(i.e., exon 1a-initiating transcripts that retain intron 1),
we find no difference between mutant and WT undif-
ferentiated cells (hESCs and iPSCs). However, their level
becomes significantly higher upon differentiation into dis-
ease-relevant cell types (NPCs and teratomas) exclusively in
C9 hESCs, and not in C9 iPSCs. We propose that methyl-936 Stem Cell Reports j Vol. 7 j 927–940 j November 8, 2016ation counteracts the effect of the expansion by downregu-
latingexon1a-initiatingmRNAspecies. In linewith this idea
are previous reports by Liu et al. (2014) and others (Bauer,
2016; Day and Roberson, 2015), which point to a mecha-
nistic link betweenhypermethylation and reduced accumu-
lation of RNA foci and dipeptide inclusions in patient cell
lines, brain samples, and HEK293T transgenic cell lines.
Our data related toC9orf72mRNA levels conflict with the
reports of others, who demonstrate a general reduction in
C9orf72 in diseased cells (Ciura et al., 2013; Cooper-Knock
et al., 2013; Donnelly et al., 2013; Waite et al., 2014; Xi
et al., 2013). These discrepancies may stem from the
different types of samples (single versusmixed type of cells)
employed. Nevertheless, even if our mutant NPCs do not
reflect the physiological levels observed in fully mature
disease-relevant cells, this model system could help to
interpret the role of methylation in disease pathogenesis
because it features both an extreme C9 hypermethylation
state and an extreme C9 hypomethylation state.
To summarize, this studyclearlydemonstrateshowreprog-
ramming excessively hypermethylates the C9 expanded
locus, and how the C9 mutation alters C9orf72 variant
transcription and processing. In addition, the current
work highlights the importance of neural differentiation in
the pathogenesis of ALS-FTD and points to the potential
role of C9 hypermethylation as a neuroprotective mecha-
nism that attenuates the accumulation of potentially toxic
repeat-containing mRNAs in C9 neurons.
Altogether, this implies that the difference between C9
hESCs and iPSCsmay be crucial for investigating the neural
phenotype of the C9/ALS-FTD disease, given that mutant
hESCs are likely to present amore accurate andmore severe
phenotype than comparable iPSCs. Recognizing that C9
hypermethylation limits the increase in intron 1-retaining
transcripts, itmay be possible in the future (with the advent
of gene editing) tomodify the C9 expanded locus by specif-
ically targeting chromatin silencing factors/DNMTs to the
region. This would affect epigenetic inactivation of exon
1a-initiating variants so as to reverse/minimize the adverse
effect of the C9 mutation in disease-affected tissues.EXPERIMENTAL PROCEDURES
hESC Cell Line Derivation and Characterization
The use of embryos carrying the C9 mutation, derived from PGD
treatment, for hESC derivation was performed in compliance
with protocols approved by the National Ethics Committee. All
cell lines were established at the Shaare Zedek Medical Center
(87/07). Cell line derivationwas carried out as previously described
(Eiges et al., 2007). All hESC lines were examined for all typical
characteristics of hESCs (for primers and conditions see Supple-
mental Experimental Procedures).
C9 iPSC Derivation
For transcription reprogramming, Yamanaka’s four retroviral
vectors expressing OCT3/4, SOX2, KLF4, and c-MYC were indi-
vidually packaged in 293T cells. Infectious viruses were collected
24 and 48 hr post transfection and immediately added to pri-
mary fibroblasts (88/11). Four days following infection the cells
were placed on mitomycin C-treated mouse embryonic fibro-
blasts (MEFs) and maintained in hESC medium. Manual isola-
tion of single clones was carried out approximately 30 days
post transfection, resulting in stable cell lines with hESC-like
morphology.
Teratoma Induction
Cells (2.5–5 3 106) were harvested, diluted 1:1 in medium/Matri-
gel, and injected subcutaneously to both sides of the back ofNOD-SCID IL2Rg/ mice. Six to eight weeks later the mice were
euthanized and tumors were isolated, sectioned, and assessed for
differentiation by H&E staining.
Neuronal Precursor Differentiation of HESCs and
iPSCs
The cells were grown on MEFs to similarly sized, defined colonies
using hESC medium. Induced embryoid body (EB) formation was
achieved by detaching colonies with collagenase IV for 30 min.
The cells were centrifuged and transferred as colonies to a Petri
dish containing hESCmediumwithout basic fibroblast growth fac-
tor (bFGF) + 5 mM dorsomorphin (catalog #11967, Cayman) and
5 mM SB431542 (SB #13031, Cayman). The EBs were cultured for
4–5 days with medium replacement every other day. For the NPC
expansion, the cells were plated onMatrigel-coated plates (without
dissociation) and cultured with KO DMEM medium + 1XN2 sup-
plement (stock X100) and 20 ng/mL bFGF for 8–10 days with
medium replacement every other day.
Chromosome Analysis
Karyotype analysis was carried out byGiemsa staining according to
standard protocol.
Southern Blot Analysis
GenomicDNAs (10–25mg)weredigestedwithEcoRI andHindIII (Fer-
mentas) restriction endonucleases, separated on 0.8% agarose gels,
blotted onto Hybond N+ membranes (Amersham), and hybridized
with a PCR Dig-labeled 576-bp probe (primer F: TTG CGA TGA CTT
TGC AGGGGA CC and primer R: CAG CGA GTA CTG TGA GAG).
RT-PCR
Total RNA was isolated from the cells by TRI Reagent extraction,
then 1 mg of RNA was reverse transcribed by random hexamer
priming andMulti Scribe reverse transcriptase (ABI). Amplification
was performed using the primers listed in Supplemental Experi-
mental Procedures using Super-Therm Taq DNA polymerase (Jain
Biologicals).
Expression of Undifferentiated Cell-Specific Markers
Undifferentiated cell cultures were examined for the expression of
undifferentiated cell-specific markers by immunostaining using
monoclonal mouse OCT3/4 (Santa Cruz Biotechnology #sc-5279,
1:50 dilution) or TRA-1-60 (Santa Cruz #sc-21705, 1:50 dilution),
together with Cy3-conjugated goat anti-mouse polyclonal anti-
bodies (Jackson Immunostaining #115-035-062, 1:100 dilution).
Nuclear staining was performed with Hoechst 33258 (Sigma
#861405). Staining for alkaline phosphatase was carried out using
an Alkaline Phosphatase Kit (SigmaDiagnostics #86R-1KT) accord-
ing to the manufacturer’s protocol.
Real-Time TaqMan PCR
TaqMan gene expression assays for C9orf72 were carried out
according to Belzil et al. (2013). qRT-PCR experiments were con-
ducted in triplicate using custom-made TaqMan-based expression
assays for transcript variants 1 (NM_145005.5), 2 (NM_018325.3),
and 3 (NM_001256054.1) individually, and altogether (adoptedStem Cell Reports j Vol. 7 j 927–940 j November 8, 2016 937
from DeJesus-Hernandez et al., 2011); for primers and probe
sequences see Supplemental Experimental Procedures). GUS
transcript (NM_000181.3) was used as housekeeping gene for
normalization of DDCt mean values.Expression of Intron 1-Retaining Transcripts
Upstream of the Repeats by qRT-PCR
Total RNA was isolated from cells by TRI reagent extraction.
RNA (1 mg) was reverse transcribed (Multi Scribe RT, ABI) with
random hexamer primers. Real-time PCR was performed using Po-
wer SYBR Green Master Mix (ABI) on an ABI 7900HT instrument.
Primers are listed in Supplemental Experimental Procedures.FACS Analysis for NCAM1-Positive Cells
NPCs were washed with PBS and dissociated to single cells using
preheated (to 37C) TrypLE Selected (Life Technologies #12563-
011) for aminimal amount of time. After cell dissociation, the cells
were resuspended with cold sterile PBS-FACS medium (Commer-
cial PBS without Ca+2 Mg+2 to prevent adhesion with FCS 10%),
and filtered through a mesh tube (#352235). From this point on-
ward everything was carried out on ice or under cold centrifuga-
tion (4C). After centrifugation 1 3 106 cells were resuspended
into 200 mL of PBS-FCS. The cells were stained directly with pri-
mary anti-NCAM1 (R&D #af2408, 1:150) and incubated on ice
for 1 hr. After staining the cells were washed two times by adding
5 mL of PBS-FCS and centrifuged at 150 3 g for 5 min. The cells
were then resuspended into the initial volume and incubated
with a secondary antibody (1:200, fluorescein isothiocyanate-con-
jugated donkey anti-goat immunoglobulin G [IgG], #705095147)
for an additional 1 hr. Control cells were stained for secondary
antibody only. The cells were washed twice and assayed by FACS.Immunostaining for Tuj1-Positive Cells in Teratoma
Sections
Paraffin-embedded tissues were sectioned (4 mm) using a micro-
tome (Leica RM2255) and transferred to silane-coated slides. After
incubation in a 60C in a dry oven for 1 hr, paraffin-embedded sec-
tionswere deparaffinized in xylene and rehydrated through graded
ethanol (100% to 50%). For antigen retrieval, sections were micro-
waved in 10mM sodium citrate buffer (pH 6.0) for 5 min. Nonspe-
cific antibody binding was blocked in PBS with 10% fetal bovine
serum and 0.3% Triton X-100 (Sigma) for 45 min. Sections were
then incubated with anti-Tuj1 antibody (rabbit IgG 1:400, Bio-
legend #845501) at 4C overnight. The secondary antibody Alexa
anti-rabbit (1:400, Life Technologies #A31572) was applied for 1 hr
at room temperature. The sections were nuclear stained by DAPI,
mounted with Vectashield (Vector Laboratories #H1000), and
examined under a fluorescent microscope.Bisulfite Sequencing
Genomic DNA (1 mg) was modified by bisulfite treatment (EZ
DNA methylation Kit, Zymo Research) and amplified by FastStart
DNA polymerase (Roche). Amplified products were cloned and
single colonies were analyzed for CpG methylation by direct
sequencing (ABI 3130). Primers are listed in Supplemental Experi-
mental Procedures.938 Stem Cell Reports j Vol. 7 j 927–940 j November 8, 2016(G4C2)n-Methylation Assay
Methylation of the G4C2-repeat itself was studied using a reported
(G4C2)n-methylation assay (Xi et al., 2015b). In brief, this assay
combines rp-PCR withmethylation-specific PCR, where each sam-
ple was amplified by rp-PCR using primers specific for methylated
versus unmethylated DNA after bisulfite conversion. The primers
were labeled by fluorescein amidite for methylated DNA amplifi-
cation (blue channel) and HEX for unmethylated DNA amplifica-
tion (green channel). Data were visualized by Genotyper software
(version 3.6, Applied Biosystems).
Chromatin Immunoprecipitation Assay
ChIP was performed using the Upstate EZTM ChIP kit, according
to the manufacturer’s protocol with slight modifications. In brief,
cells were harvested and then fixed, quenched, and washed in
50-mL tubes. Sonication was carried out using a Vibra Cell
VCX130 with a 3-mm microtip and 30% amplitude, in five cycles
of 10 s and 30 s rest on ice. Immunoprecipitation was performed
using an anti-H3K27me3 (Abcam #6002) and anti-H3K9me3
(Abcam #8898) antibody. Immunoprecipitation efficiency was
evaluated by HOXA9 (enriched in H3K9me3 and H3K27me3 in
pluripotent stem cells). Real-time PCR was carried out on an ABI
7900HT instrument (primers are listed in Supplemental Experi-
mental Procedures). DDCt values were normalized according to
a negative control (APRT) to account for histone modification
enrichment.
RNA Deep Sequencing
RNA was extracted using TRI Reagent (Sigma). Depletion of rRNA
was performed using the Ribominus kit (Invitrogen). RNase-R
treatments were performed by adding 3 U of RNase-R (Epicenter
Biotechnologies) per milligram of RNA and 15-min incubation at
37C. cDNA libraries were generated using the TruSeq RNA sample
preparation kit and protocol (Illumina), and stranded, ligation-
based libraries were sequenced as previously described (Engreitz
et al., 2013). RNA-seq reads were aligned to the genome (hg19)
using STAR. Coverage of C9orf72 second exon (chr9:27566674-
27567162) and first intron (chr9:27567163-27573426) were calcu-
lated using the samtools depth tool. We normalized the total
coverage values to the length of the exon/intron to obtain average
coverage per base.
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